Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease

Experimental and Therapeutic Medicine

Volumn 11, Issue 4, 2016, Pages 1487-1492

  Alkhatatbeh, Mohammad J ^a   Lincz, Lisa F ^b   Thorne, Rick F ^c  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Microparticles; Non alcoholic fatty liver disease; Oleic acid; Simvastatin; Steatosis

Indexed keywords

DYE; LIPOCORTIN 5; OIL RED O; SIMVASTATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; EXPERIMENTAL FATTY LIVER; FLOW CYTOMETRY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; LIPID STORAGE; LOW DRUG DOSE; METABOLIC SYNDROME X; MICROPARTICLE QUANTIFICATION; NONALCOHOLIC FATTY LIVER; OLEIC ACID INDUCED STEATOSIS; OPTICAL DENSITY; PHASE CONTRAST MICROSCOPY; QUANTITATIVE ANALYSIS;

EID: 84958766812     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3069     Document Type: Article

References (33)

1. Green CJ and Hodson L: The influence of dietary fat on liver fat accumulation. Nutrients 6: 5018-5033, 2014.
2. Baraona E and Lieber CS: Effects of ethanol on lipid metabolism. J Lipid Res 20: 289-315, 1979.
3. Souza MR, Diniz Mde F, Medeiros-Filho JE and Araújo MS: Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 49: 89-96, 2012.
4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107: 450-455, 1999.
5. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T and Ratziu V: Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 35: 23-28, 2011.
6. Onnerhag K, Nilsson PM and Lindgren S: Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol 49: 1111-1118, 2014.
7. Centis E, Marzocchi R, Suppini A, Dalle Grave R, Villanova N, Hickman IJ and Marchesini G: The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des 19: 5270-5279, 2013.
8. Angelico F, Burattin M, Alessandri C, Del Ben M and Lirussi F: Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev: CD005166, 2007.
9. Tolman KG and Dalpiaz AS: Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag 3: 1153-1163, 2007.
10. Basaranoglu M, Acbay O and Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steato- hepatitis. J Hepatol 31: 384, 1999.
11. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M and Chayama K: Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57: 1711-1728, 2008.
12. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O and Memik F: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17: 713-718, 2003.
13. Calderon RM, Cubeddu LX, Goldberg RB and Schiff ER: Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma. Mayo Clin Proc 85: 349-356, 2010.
14. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S and Aramin H: Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 12: CD008623, 2013.
15. Egan M and Prasad S: PURLs: Statins for patients with nonalcoholic fatty liver? J Fam Pract 60: 536-538, 2011.
16. Nseir W and Mahamid M: Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep 15: 305, 2013.
17. Dima A, Marinescu AG and Dima AC: Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med 50: 19-25, 2012.
18. Cui W, Chen SL and Hu KQ: Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2: 95-104, 2010.
19. 2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother Res 25: 588-596, 2011.
20. Susztak K, Ciccone E, McCue P, Sharma K and Böttinger EP: Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2: e45, 2005.
21. Rossi J, Rouleau L, Tardif JC and Leask RL: Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress. Life Sci 87: 92-99, 2010.
22. Alkhatatbeh MJ, Enjeti AK, Acharya S, Thorne RF and Lincz LF: The origin of circulating CD36 in type 2 diabetes. Nutr Diabetes 3: e59, 2013.
23. Robert S, Poncelet P, Lacroix R, Arnaud L, Giraudo L, Hauchard A, Sampol J and Dignat-George F: Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: A first step towards multicenter studies? J Thromb Haemost 7: 190-197, 2009.
24. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS and Dignat-George F; ISTH SSC Workshop: Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: Results of the International Society on Thrombosis and Haemostasis SSC collaborative workshop. J Thromb Haemost 8: 2571-2574, 2010.
25. Hargett LA and Bauer NN: On the origin of microparticles: From 'platelet dust' to mediators of intercellular communication. Pulm Circ 3: 329-340, 2013.
26. Gomez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV and O'Connor JE: A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165: 106-116, 2007.
27. de Keyser CE, Koehler EM, Schouten JN, Visser LE, Hofman A, Janssen HL and Stricker BH: Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig Liver Dis 46: 720-725, 2014.
28. Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33: 1569-1582, 1992.
29. Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
30. Stein EA, Lane M and Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 81: 66B-69B, 1998.
31. Huang X, Ma J, Xu J, Su Q and Zhao J: Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Mol Med Rep 11: 2334-2340, 2015.
32. Kah J, Wüstenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G and Sass G: Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 28: 1077-1083, 2012.
33. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med 26: 735-741, 2010.